July 12, 2012, Parsippany, NJ, USA – The STA® – Rivaroxaban Calibrator and Controls are highly specific, automation-ready products for determining the rivaroxaban concentration in plasma when used in conjunction with the STA® - Liquid Anti-Xa assay. This method was shown to have favorable performance with respect to its linearity and coefficient of variation (CV) in a recent publication.1

June 29, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. announces products to suit a variety of clinical research needs for factor VII (FVII). Factor VII is a zymogen that upon activation to its active form, factor VIIa (FVIIa) together with Tissue Factor (TF) comprises the first step in the extrinsic pathway of blood coagulation leading to thrombin formation and subsequent formation of the fibrin clot. Fibrin...

April 10, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI) has joined AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) dedicated to addressing the policy and regulatory issues facing in vitro diagnostic companies both in the United States and abroad.

January 4, 2012, Parsippany, NJ, USA – Diagnostica Stago announces three new products to suit a variety of clinical research needs for procoagulant and total microparticle detection. Microparticles are tissue factor-bearing phospholipid vesicles that have often been the subject of clinical research studies into various conditions such as cancer, diabetes, sickle cell disorder, as well as parasitic and viral infectio...

July 1, 2011, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI), recently finalized the acquisition of Thrombinoscope BV, based in Maastricht, The Netherlands. This company, researches, develops and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram® (CAT) system. This system is available for research-only use – and should not be used for diagnostic purposes.